Cerebrospinal fluid GFAP is a predictive biomarker for conversion to dementia and Alzheimer’s disease-associated biomarkers alterations among de novo Parkinson’s disease patients: a prospective cohort study
Abstract Background Dementia is a prevalent non-motor manifestation among individuals with advanced Parkinson’s disease (PD). Glial fibrillary acidic protein (GFAP) is an inflammatory marker derived from astrocytes. Research has demonstrated the potential of plasma GFAP to forecast the progression t...
Main Authors: | Tingting Liu, Hongzhou Zuo, Di Ma, Dan Song, Yuying Zhao, Oumei Cheng |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-07-01
|
Series: | Journal of Neuroinflammation |
Subjects: | |
Online Access: | https://doi.org/10.1186/s12974-023-02843-5 |
Similar Items
-
Cerebrospinal fluid neurofilament dynamic profiles predict cognitive progression in individuals with de novo Parkinson’s disease
by: Ze-Hu Sheng, et al.
Published: (2022-12-01) -
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
by: Ka Young Kim, et al.
Published: (2023-05-01) -
Performance of biomarkers NF-L, NSE, Tau and GFAP in blood and cerebrospinal fluid in rat for the detection of nervous system injury
by: Katerina Vlasakova, et al.
Published: (2024-01-01) -
Whether Serum Glial Fibrillary Acidic Protein (GFAP) Can Be Used as a Diagnostic Biomarker in Patients With Glioblastoma?
by: Charandeep Singh Gandhoke, et al.
Published: (2020-01-01) -
Update on CSF Biomarkers in Parkinson’s Disease
by: Eun Hae Kwon, et al.
Published: (2022-02-01)